http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 10 Jun 2026 16:10:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Guggenheim+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+reiterate+our+positive+view%27/26629961.html <p>Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)</p><p>The analyst comments "Sanofi (SNY)'s decision to stop the Phase 3 MOBILIZE study of riliprubart in SOC-refractory CIDP at the pre-specified interim has driven fair investor scrutiny to DNTH's CAPTIVATE program, but on balance we see today's news as constructive for claseprubart. Mgmt views it as a net positive, and we agree, for four reasons: (1) potency — claseprubart is ~7× more potent than riliprubart at IC90, but Sanofi was only dosing ~4× higher, implying riliprubart likely failed to achieve the target coverage required http://www.streetinsider.com/Analyst+Comments/Guggenheim+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+reiterate+our+positive+view%27/26629961.html Wed, 10 Jun 2026 16:10:32 -0400 DNTH SNY http://www.streetinsider.com/Analyst+Comments/Guggenheim+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+reiterate+our+positive+view%27/26629961.html <p>Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)</p><p>The analyst comments "Sanofi (SNY)'s decision to stop the Phase 3 MOBILIZE study of riliprubart in SOC-refractory CIDP at the pre-specified interim has driven fair investor scrutiny to DNTH's CAPTIVATE program, but on balance we see today's news as constructive for claseprubart. Mgmt views it as a net positive, and we agree, for four reasons: (1) potency — claseprubart is ~7× more potent than riliprubart at IC90, but Sanofi was only dosing ~4× higher, implying riliprubart likely failed to achieve the target coverage required http://www.streetinsider.com/Analyst+Comments/Guggenheim+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+reiterate+our+positive+view%27/26629961.html Wed, 10 Jun 2026 16:10:32 -0400 DNTH SNY http://www.streetinsider.com/Hot+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html <p>Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).</p><p>The analyst comments "Sanofi announced it is stopping its Phase 3 study evaluating riliprubart in refractory CIDP patients, a C1s inhibitor and direct competitor to claseprubart, due to an interim readout analysis suggesting lack of efficacy (but not safety). Recall, Sanofi is running two phase 3 studies to support a potential BLA submission in CIDP, with the other Phase 3 comparing riliprubart vs. IVIG (readout pending). In contrast, Dianthus is running a single placebo-controlled study to support a potential sBLA for claseprubart http://www.streetinsider.com/Hot+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html Wed, 10 Jun 2026 13:37:50 -0400 DNTH SNY http://www.streetinsider.com/Hot+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html <p>Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).</p><p>The analyst comments "Sanofi announced it is stopping its Phase 3 study evaluating riliprubart in refractory CIDP patients, a C1s inhibitor and direct competitor to claseprubart, due to an interim readout analysis suggesting lack of efficacy (but not safety). Recall, Sanofi is running two phase 3 studies to support a potential BLA submission in CIDP, with the other Phase 3 comparing riliprubart vs. IVIG (readout pending). In contrast, Dianthus is running a single placebo-controlled study to support a potential sBLA for claseprubart http://www.streetinsider.com/Hot+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html Wed, 10 Jun 2026 13:37:50 -0400 DNTH SNY http://www.streetinsider.com/Analyst+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html <p>Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).</p><p>The analyst comments "Sanofi announced it is stopping its Phase 3 study evaluating riliprubart in refractory CIDP patients, a C1s inhibitor and direct competitor to claseprubart, due to an interim readout analysis suggesting lack of efficacy (but not safety). Recall, Sanofi is running two phase 3 studies to support a potential BLA submission in CIDP, with the other Phase 3 comparing riliprubart vs. IVIG (readout pending). In contrast, Dianthus is running a single placebo-controlled study to support a potential sBLA for claseprubart http://www.streetinsider.com/Analyst+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html Wed, 10 Jun 2026 13:37:50 -0400 DNTH SNY http://www.streetinsider.com/Analyst+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html <p>Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).</p><p>The analyst comments "Sanofi announced it is stopping its Phase 3 study evaluating riliprubart in refractory CIDP patients, a C1s inhibitor and direct competitor to claseprubart, due to an interim readout analysis suggesting lack of efficacy (but not safety). Recall, Sanofi is running two phase 3 studies to support a potential BLA submission in CIDP, with the other Phase 3 comparing riliprubart vs. IVIG (readout pending). In contrast, Dianthus is running a single placebo-controlled study to support a potential sBLA for claseprubart http://www.streetinsider.com/Analyst+Comments/Raymond+James+on+Dianthus+Therapeutics+%28DNTH%29+Amid+15%25+Down+Day%3A+%27We+See+Overall+Positive+Readthrough+to+Claseprubart%27/26628997.html Wed, 10 Jun 2026 13:37:50 -0400 DNTH SNY http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+see+weakness+as+a+buying+opportunity%27/26629124.html <p>TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).</p><p>The analyst comments "SNY stopping riliprubart's MOBILIZE on futility is molecule/trial-specific rather than thesisbreaking for DNTH. DNTH mgmt notes Ph3 CAPTIVATE for claseprubart (C1s) continues to show high response rates across all 3 pt segments, including IVIg-refractory, with a more stringent responder rate definition, stronger potency, and potentially smaller/faster Ph3. We see weakness as a buying opportunity."</p><p>For an analyst ratings summary and ratings history on Dianthus Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=DNTH">click here</a>. For more ratings news on Dianthus Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=DNTH&amp;type=analyst">click here</a>.</p><p>Shares of Dianthus Therapeutics closed at $84.57 yesterday.</p> http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+see+weakness+as+a+buying+opportunity%27/26629124.html Wed, 10 Jun 2026 13:37:06 -0400 DNTH SNY http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+see+weakness+as+a+buying+opportunity%27/26629124.html <p>TD Cowen analyst Yaron Werber reiterated a Buy rating on Dianthus Therapeutics (NASDAQ: DNTH).</p><p>The analyst comments "SNY stopping riliprubart's MOBILIZE on futility is molecule/trial-specific rather than thesisbreaking for DNTH. DNTH mgmt notes Ph3 CAPTIVATE for claseprubart (C1s) continues to show high response rates across all 3 pt segments, including IVIg-refractory, with a more stringent responder rate definition, stronger potency, and potentially smaller/faster Ph3. We see weakness as a buying opportunity."</p><p>For an analyst ratings summary and ratings history on Dianthus Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=DNTH">click here</a>. For more ratings news on Dianthus Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=DNTH&amp;type=analyst">click here</a>.</p><p>Shares of Dianthus Therapeutics closed at $84.57 yesterday.</p> http://www.streetinsider.com/Analyst+Comments/TD+Cowen+Defending+Dianthus+Therapeutics+%28DNTH%29%3A+%27We+see+weakness+as+a+buying+opportunity%27/26629124.html Wed, 10 Jun 2026 13:37:06 -0400 DNTH SNY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Jun+08/26613831.html si-local-file:///var/storage/secattach/20260608/26613831.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Jun+08/26613831.html Mon, 08 Jun 2026 06:07:00 -0400 O.00356206 SAN SNY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Jun+08/26613831.html si-local-file:///var/storage/secattach/20260608/26613831.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Jun+08/26613831.html Mon, 08 Jun 2026 06:07:00 -0400 O.00356206 SAN SNY http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Jun+08/26613831.html si-local-file:///var/storage/secattach/20260608/26613831.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Sanofi++++++++++++++++++++For%3A+Jun+08/26613831.html Mon, 08 Jun 2026 06:07:00 -0400 O.00356206 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Press+Releases/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html <p align="justify"><em>Sanofi launches 2026 global employee stock purchase plan<br/><br/></em></p> <p align="justify"><strong>Paris, June 4, 2026.</strong> Sanofi’s global employee shareholder plan, Action 2026, opens on June 9, 2026, to around 75,000 employees in 52 countries. Now in its 12th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2025 alone, more than 31,000 Sanofi employees - 44% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.93% http://www.streetinsider.com/Globe+Newswire/Press+Release%3A+Sanofi+launches+2026+global+employee+stock+purchase+plan/26601515.html Thu, 04 Jun 2026 04:07:00 -0400 A.22211465 A.26800952 O.00356206 O.00711722 O.54450828 SAN SNY